<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060618</url>
  </required_header>
  <id_info>
    <org_study_id>TROPISMVC</org_study_id>
    <secondary_id>2008-007208-28</secondary_id>
    <nct_id>NCT01060618</nct_id>
  </id_info>
  <brief_title>Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term</brief_title>
  <acronym>TROPISMVC</acronym>
  <official_title>Estudio Comparativo de Dos métodos Para Predecir el Uso de Co-receptores Por el Virus de la Inmunodeficiencia 1 (HIV-1): el Ensayo fenotípico (Trofile ESTA®) y la Respuesta virológica a Corto Plazo a un Antagonista de CCR5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion para el Estudio de las Enfermedades Infecciosas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociacion para el Estudio de las Enfermedades Infecciosas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The summary of the Study is to compare two methods in order to predict how the 1-HIV will use
      a co-receptor: the use of an accredited test (TROFILE ESTA®) and the viral response to a CCR5
      antagonist in the short term.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if there is a correlation between the Trofile ESTA® test for viral tropism and the viral load reduction after a short treatment with maraviroc in naïve patients (patients with no previous HAART)</measure>
    <time_frame>10 days of treatment per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish a viral load reduction cut point, which would differentiate R5-tropic virus from non-R5 tropic virus(X4/dual/mixed).</measure>
    <time_frame>1 month per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the viral response to a CCR5 antagonist according to the viral tropism identified in the phenotypic Study.</measure>
    <time_frame>1 month per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment throughout the Study</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maraviroc effects assessment in the drug-resistance evolution in naïve patients</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tropism changes assessment since the Screening period</measure>
    <time_frame>1 month per patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc + Trofile ESTA®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maraviroc + Trofile ESTA® (diagnose test)</intervention_name>
    <description>The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc</description>
    <arm_group_label>Maraviroc + Trofile ESTA®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to give, sign and date the Informed Consent Form to participate in
             the Study and to donate their samples for cell and molecular Studies, after receiving
             the appropriate information about the Study design, the main objective of the Study
             and the potential risks.

          -  Patients aged &gt;18.

          -  Patients with chronic HIV infection

          -  Patients with no previous HAART (naïve patients).

          -  Patients that do not meet HAART starting criteria.

          -  Viral load &gt;1.000 HIV RNA copies/mL

          -  Patients able to understand the Study objectives and able to perform frequent visits
             to the Study Site.

        Exclusion Criteria:

          -  Prior HAART (regardless of the HAART type).

          -  Pregnancy or willingness to get pregnant during the Study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>280007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

